Lilly shares slip as FDA seeks more Alzheimer's drug data

Eli Lilly shares slipped Friday after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment.

Lilly said the Food and Drug Administration wants information from at least 100 patients who received a minimum of 12 months of continued treatment on donanemab. The drugmaker gave the update after markets closed Thursday.

The potential treatment aims to clear a plaque from the brain that is a key hallmark of the mind-robbing disease.

Lilly said it had more than 100 patients in the study used for its accelerated approval application. But many were able to stop taking the drug as early as 6 months into treatment due to the reduction in plaque.